Overview

A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This study will compare the plasma pharmacokinetics of a single 125mg oral dose of palbociclib in the presence and absence of rifampin-mediated enzyme induction in a fixed-sequence two-period study.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Palbociclib
Rifampin